<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00848068</url>
  </required_header>
  <id_info>
    <org_study_id>C-07-61</org_study_id>
    <nct_id>NCT00848068</nct_id>
  </id_info>
  <brief_title>Evaluation of FID 114657 on Tear Film Lipid Layer Thickness</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effects of FID 114657 on the tear film lipid layer thickness of patients with&#xD;
      dry eye.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>lipid layer thickness</measure>
    <time_frame>Instill assigned test article to the right eye and begin timing the examination process. Measure lipid layer thickness at 1 minute, 5 minutes, 15 minutes and 60 minutes post instillation</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>OD (Right Eye)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>FID 114657 or OPTIVE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OS (Left eye)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>FID 114657 or OPTIVE</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>FID 114657</intervention_name>
    <description>artificial tears</description>
    <arm_group_label>OD (Right Eye)</arm_group_label>
    <arm_group_label>OS (Left eye)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>OPTIVE Lubricant Eye Drops</intervention_name>
    <description>artificial tears</description>
    <arm_group_label>OD (Right Eye)</arm_group_label>
    <arm_group_label>OS (Left eye)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent document and HIPAA privacy document must be read, signed and dated by&#xD;
             the patient or legally authorized representative before conducting any procedures.&#xD;
&#xD;
          -  Patients (minimum age 18) with dry eye. Criteria for the diagnosis must include the&#xD;
             following characteristics:&#xD;
&#xD;
               -  Positive response to the question, &quot;Do you ever feel your eyes?&quot;;&#xD;
&#xD;
               -  Baseline LLT value of ≤75nm (OU), not varying by more than ±15 nm over the course&#xD;
                  of a 10-minute observation period, difference in LLT between the two eyes must be&#xD;
                  ≤15nm, and increase in LLT after three forceful blinks must be ≤15nm.&#xD;
&#xD;
          -  Patients must have best-corrected Snellen visual acuity of 20/70 or better in each&#xD;
             eye.&#xD;
&#xD;
          -  Able and willing to follow study instructions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of topical ocular drops within 12 hours of the study visit; or use of a topical&#xD;
             ocular ointment within 36 hours of the study visit. In addition, use of any&#xD;
             concomitant topical ocular drugs during the study period.&#xD;
&#xD;
          -  History or evidence of ocular or intraocular surgery in either eye within the past six&#xD;
             months.&#xD;
&#xD;
          -  History or evidence of serious ocular trauma in either eye within the past six months.&#xD;
&#xD;
          -  History of intolerance or hypersensitivity to any component of the study medications.&#xD;
&#xD;
          -  History of and/or current evidence of glaucoma or ocular hypertension in either eye.&#xD;
&#xD;
          -  History of and/or current evidence of active intraocular inflammation in either eye&#xD;
             (i.e., retina/macula/choroid).&#xD;
&#xD;
          -  History or evidence of epithelial herpes simplex keratitis (dendritic keratitis);&#xD;
             vaccinia; active or recent varicella viral disease of the cornea and/or conjunctiva;&#xD;
             ocular rosacea; chronic bacterial disease of the cornea and/or conjunctiva and/or&#xD;
             eyelids; mycobacterial infection of the eye; and/or fungal disease of the eye.&#xD;
&#xD;
          -  Ocular conditions such as active acute blepharitis, conjunctival infections, iritis,&#xD;
             conjunctival abnormalities (including pinguecula greater than 1mm in diameter, located&#xD;
             closer than 2mm to the limbus or elevated more than 0.2mm), eyelid abnormalities&#xD;
             (including entropion and ectropion) or any other ocular condition that may, in the&#xD;
             opinion of the investigator, preclude the safe administration of the test articles.&#xD;
&#xD;
          -  Patients using systemic medications that may contribute to dry eye (e.g. cold and&#xD;
             allergy medications, tricyclic antidepressants, hormone replacement therapies) may not&#xD;
             be enrolled in the study unless they have been on a stable dosing regimen for a&#xD;
             minimum of 30 days prior to the study visit.&#xD;
&#xD;
          -  Any ocular or systemic medical condition that might influence the tear film (other&#xD;
             than dry eye).&#xD;
&#xD;
          -  Individuals unwilling to discontinue contact lens wear during the study period.&#xD;
             Contact lens wear must have been discontinued a minimum of 12 hours prior to the study&#xD;
             visit.&#xD;
&#xD;
          -  Individuals unwilling to discontinue use of cosmetics (such as eyeliner, mascara or&#xD;
             eye shadow) or facial creams on or around the eyelids on the day of the study.&#xD;
&#xD;
          -  Participation in an investigational drug or device study within 30 days of entering&#xD;
             this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>February 19, 2009</study_first_submitted>
  <study_first_submitted_qc>February 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2009</study_first_posted>
  <last_update_submitted>February 1, 2012</last_update_submitted>
  <last_update_submitted_qc>February 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lipid layer thickness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Lubricant Eye Drops</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

